ADC Therapeutics
ADCT
About: ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Employees: 263
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
137% more capital invested
Capital invested by funds: $77.3M [Q1] → $183M (+$106M) [Q2]
100% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 4 (+2) [Q2]
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
13.52% more ownership
Funds ownership: 55.36% [Q1] → 68.88% (+13.52%) [Q2]
4% more funds holding
Funds holding: 83 [Q1] → 86 (+3) [Q2]
30% less call options, than puts
Call options by funds: $203K | Put options by funds: $291K
60% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 40
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
Guggenheim
Michael Schmidt
|
$10
|
Buy
Reiterated
|
13 Aug 2025 |
|
RBC Capital
Leonid Timashev
|
$5
|
Outperform
Maintained
|
20 Jun 2025 |
Financial journalist opinion
